These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23274014)

  • 21. Restenosis in gold-coated renal artery stents.
    Nolan BW; Schermerhorn ML; Powell RJ; Rowell E; Fillinger MF; Rzucidlo EM; Wyers MC; Whittaker D; Zwolak RM; Walsh DB; Cronenwett JL
    J Vasc Surg; 2005 Jul; 42(1):40-6. PubMed ID: 16012450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Percutaneous coronary interventions in the diabetic patient: where do we stand?
    Bittl JA
    Circ Cardiovasc Interv; 2015 Apr; 8(4):e001944. PubMed ID: 25788342
    [No Abstract]   [Full Text] [Related]  

  • 23. Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty.
    Al Suwaidi J; Holmes DR; Salam AM; Lennon R; Berger PB
    Am Heart J; 2004 May; 147(5):815-22. PubMed ID: 15131536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioresorbable scaffolding after drug-coated balloons: a new chapter of the "leave nothing behind" saga.
    Cortese B; Sebik R; Seregni R; Silva PL
    Int J Cardiol; 2014 May; 173(3):e67-9. PubMed ID: 24704408
    [No Abstract]   [Full Text] [Related]  

  • 25. Percutaneous intervention of left main coronary artery disease: a fresh look at a class III recommendation.
    Diamond MJ; Gujral J; Kapoor D
    South Med J; 2005 Nov; 98(11):1153-4. PubMed ID: 16351042
    [No Abstract]   [Full Text] [Related]  

  • 26. [Percutaneous coronary intervention in patients with diabetes].
    vom Dahl J
    Dtsch Med Wochenschr; 2002 Mar; 127(13):689-94. PubMed ID: 11928061
    [No Abstract]   [Full Text] [Related]  

  • 27. [Quality of life in diabetic patients with coronary artery disease treated with percutaneous coronary angioplasty].
    Przewłocki T; Podolec P; Tracz W; Syty M; Piatek J; Ryniewicz W; Pasowicz M; Goncerz G
    Przegl Lek; 2000; 57(5):278-82. PubMed ID: 11057117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cost analysis of percutaneous coronary intervention and coronary artery bypass grafting in Japan and USA].
    Chino M; Sasaki T
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():632-7. PubMed ID: 12735043
    [No Abstract]   [Full Text] [Related]  

  • 29. Dexamethasone-eluting vascular stents.
    Hämäläinen M; Nieminen R; Uurto I; Salenius JP; Kellomäki M; Mikkonen J; Kotsar A; Isotalo T; Teuvo Tammela LJ; Talja M; Moilanen E
    Basic Clin Pharmacol Toxicol; 2013 May; 112(5):296-301. PubMed ID: 23374962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease. Insights from the SYNTAX run-in phase.
    Kappetein AP; Dawkins KD; Mohr FW; Morice MC; Mack MJ; Russell ME; Pomar J; Serruys PW
    Eur J Cardiothorac Surg; 2006 Apr; 29(4):486-91. PubMed ID: 16497510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of peripheral arterial disease in patients undergoing percutaneous coronary intervention with intracoronary stents.
    Singh M; Lennon RJ; Darbar D; Gersh BJ; Holmes DR; Rihal CS
    Mayo Clin Proc; 2004 Sep; 79(9):1113-8. PubMed ID: 15357032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Percutaneous coronary revascularization of diabetic patients in the era of drug-eluting stents.
    Kereiakes DJ; Young JJ
    Rev Cardiovasc Med; 2005; 6 Suppl 1():S48-58. PubMed ID: 15665798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug eluting stents for saphenous vein graft interventions.
    Banerjee S; Master R; Iqbal A; Brilakis ES
    Minerva Cardioangiol; 2011 Jun; 59(3):235-8. PubMed ID: 21516072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of chronic kidney disease and diabetes on percutaneous coronary intervention outcomes.
    Lepor NE
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S38-48. PubMed ID: 17224890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective and efficient strategies for coronary revascularization in the drug-eluting stent era.
    Lepor NE; Madyoon H; Kereiakes D
    Rev Cardiovasc Med; 2002; 3 Suppl 5():S38-50. PubMed ID: 12478234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Coronary revascularization of coronary artery disease in patients with diabetes].
    Tsuboi S; Miyauchi K
    Nihon Rinsho; 2011 Feb; 69(2):329-34. PubMed ID: 21387685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials.
    Kirtane AJ; Ellis SG; Dawkins KD; Colombo A; Grube E; Popma JJ; Fahy M; Leon MB; Moses JW; Mehran R; Stone GW
    J Am Coll Cardiol; 2008 Feb; 51(7):708-15. PubMed ID: 18279734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coronary artery revascularisation: selecting the appropriate strategy.
    Adams MR
    Intern Med J; 2013 Jan; 43(1):18-22. PubMed ID: 23324088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of diamond-like carbon-coated stents versus uncoated stainless steel stents in coronary artery disease.
    Airoldi F; Colombo A; Tavano D; Stankovic G; Klugmann S; Paolillo V; Bonizzoni E; Briguori C; Carlino M; Montorfano M; Liistro F; Castelli A; Ferrari A; Sgura F; Di Mario C
    Am J Cardiol; 2004 Feb; 93(4):474-7. PubMed ID: 14969628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
    Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
    N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.